文献速递炎症性肠病

维得利珠单抗与托法替布联合治疗难治性溃疡性结肠炎的前瞻性队列研究

Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti-TNF and a Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2025-08-04

本研究在抗TNF及第二种进阶治疗均无效的中重度溃疡性结肠炎患者中,评估维得利珠单抗联合托法替布(VETO)的疗效与安全性。24例接受VETO治疗并随访24周,第24周17例达临床应答、14例达无激素缓解、7例达内镜缓解,Mayo评分显著改善,无严重不良事件。

要点

  • VETO联合治疗在抗TNF及二线治疗失败的UC患者中安全有效。
  • 第24周超半数患者达临床缓解,Mayo评分显著改善。
  • 仅2例出现伪膜性结肠炎并经万古霉素治愈,无严重不良事件。

核心结论

  • VETO联合治疗对抗TNF及二线进阶治疗均无效的溃疡性结肠炎患者有效且安全,24周时超过半数达临床缓解。

研究设计与样本

  • 前瞻性队列研究嵌套于随机试验,纳入中重度活动期(Mayo评分6-12)溃疡性结肠炎患者,先随机接受维得利珠单抗或托法替布单药,无应答者接受VETO联合治疗并随访24周。
  • 91例患者中38例随机至维得利珠单抗、40例至托法替布;分别有14例和15例无应答,其中24例接受VETO治疗,随访34±16.1周。
  • VETO治疗前二线治疗中位持续时间为21周;5例无应答者接受替代干预或失访。

主要发现

  • 第8周:17例达临床应答,5例达缓解,3例接受结肠切除术。
  • 第24周:17例达临床应答,14例达无激素缓解,7例达内镜缓解。
  • Mayo评分显著改善(平均差值5.33±0.53;p<0.01)。
  • 2例发生伪膜性结肠炎,经万古霉素治疗后缓解;无严重不良事件发生。

关键数值与推荐

  • 主要结局为第24周临床应答与无激素缓解的复合终点。
  • 次要结局包括第8周临床应答和缓解、第24周内镜缓解及治疗相关不良事件的发生率和严重程度。
  • 疾病活动度纳入标准为Mayo评分6-12分。

临床怎么用

  • 对于抗TNF及二线进阶治疗均无效的难治性溃疡性结肠炎患者,可考虑维得利珠单抗与托法替布联合治疗。
  • 联合治疗期间需监测不良事件,包括伪膜性结肠炎等感染并发症。

局限性

  • 样本量较小,接受VETO治疗者仅24例。
  • 随访时间有限(34±16.1周),长期疗效与安全性未知。
  • 5例无应答者接受替代干预或失访,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of refractory ulcerative colitis (UC) unresponsive to advanced therapies is challenging. Combination therapy is a potential strategy. AIM: To evaluate the safety and efficacy of vedolizumab and tofacitinib combination (VETO) therapy in patients with UC refractory to anti-TNF and unresponsive to either agent as monotherapy. METHODS: We prospectively recruited patients with moderate-to-severe disease activity (Mayo score: 6-12). Patients were randomised to receive vedolizumab or tofacitinib. Non-responders were offered VETO therapy and followed for 24 weeks. The primary outcome was a combined clinical response and corticosteroid-free remission at week 24. Secondary outcomes included clinical response and remission at week 8, endoscopic remission at week 24 and incidence and severity of treatment-related adverse events. RESULTS: Of 91 patients, 38 were randomised to vedolizumab and 40 to tofacitinib. Fourteen and 15, respectively, were non-responders to vedolizumab and tofacitinib; 24 received VETO with follow-up of 34 ± 16.1 weeks. Median second-line therapy duration before VETO was 21 weeks. Five non-responders received alternative interventions or were lost to follow-up. At week 8, 17 achieved clinical response and five achieved remission; three underwent colectomy. At week 24, response and corticosteroid-free remission were seen in 17 and 14, respectively; 7 achieved endoscopic remission. Mayo scores improved significantly (mean difference 5.33 ± 0.53; p < 0.01). Two patients developed pseudomembranous colitis that resolved with vancomycin. No severe adverse events occurred. CONCLUSION: VETO was effective and safe in patients with UC refractory to anti-TNF and second-line therapies, with over half achieving clinical remission by 24 weeks.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Neelam PB, Mekala D, Patel R, et al. Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti-TNF and a Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial. Aliment Pharmacol Ther. 2025. PMID: 40755085. doi:10.1111/apt.70309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。